Mining hidden knowledge for drug safety assessment: Topic modeling of LiverTox as a case study

BMC Bioinformatics

Volumn 15, Issue 17, 2014, Pages

  Yu, Ke ^a   Zhang, Jie ^a   Chen, Minjun ^a   Xu, Xiaowei ^a,b   Suzuki, Ayako ^c   Ilic, Katarina ^d   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Department of Information Science ^*  (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

BIG DATA; DATABASE SYSTEMS; DRUG PRODUCTS; HEALTH; KNOWLEDGE MANAGEMENT; MEDICAL COMPUTING; PUBLIC HEALTH; SAFETY ENGINEERING;

ACUTE LIVER FAILURE; CLINICAL INFORMATION; DRUG DEVELOPMENT; MULTIPLE DISCIPLINES; NATIONAL INSTITUTES OF HEALTH; PROOF OF CONCEPT; SCIENTIFIC INVESTIGATION; TEXTUAL PATTERNS;

DATA MINING;

ADVERSE DRUG REACTION; BIOLOGICAL MODEL; DATA MINING; FACTUAL DATABASE; HUMAN; PROCEDURES; SAFETY; TOXIC HEPATITIS;

DATA MINING; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, BIOLOGICAL; SAFETY MANAGEMENT;

EID: 84961875669     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-S17-S6     Document Type: Article

References (22)

1. Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ: LiverTox: a website on drug-induced liver injury. Hepatology. 2013, 57 (3): 873-874. 10.1002/hep.26175.
2. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P: A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010, 6: 343-
3. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P: Drug target identification using side-effect similarity. Science. 2008, 321 (5886): 263-266. 10.1126/science.1158140.
4. Fang H, Su Z, Wang Y, Miller A, Liu Z, Howard PC, Tong W, Lin SM: Exploring the FDA Adverse Event Reporting System to Generate Hypotheses for Monitoring of Disease Characteristics. Clin Pharmacol Ther. 2014, 95 (5): 496-498. 10.1038/clpt.2014.17.
5. Blei DM, Ng AY, Jordan MI: Latent Dirichlet allocation. J Mach Learn Res. 2003, 3 (4-5): 993-1022.
6. Bisgin H, Liu Z, Fang H, Xu X, Tong W: Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics. 2011, 12 (Suppl 10): S11-10.1186/1471-2105-12-S10-S11.
7. Bisgin H, Liu Z, Kelly R, Fang H, Xu X, Tong W: Investigating drug repositioning opportunities in FDA drug lables through topic modeling. BMC Bioinformatics. 2012, 13 (Suppl 15): S6-10.1186/1471-2105-13-S15-S6.
8. Hofmann T: Probabilistic Latent Semantic Indexing. Proceedings of the Twenty-Second Annual International SIGIR Conference on Research and Development in Information Retrieval (SIGIR-99). 1999, 50-57.
9. Griffiths TL, Steyvers M: A probabilistic approach to semantic representation. Proceedings of the Twenty-Fourth Annual Conference of Cognitive Science Society. 2002, 381-386.
10. Griffiths TL, Steyvers M: Finding scientific topics. Proc Natl Acad Sci USA. 2004, 101 (Suppl 1): 5228-5235.
11. McCallum AK: MALLET: a machine learning for language toolkit. 2002, [ http://mallet.cs.umass.edu ]
12. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW: Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010, 33 (6): 503-522. 10.2165/11535340-000000000-00000.
13. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study G: Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010, 52 (6): 2065-2076. 10.1002/hep.23937.
14. Mindikoglu AL, Magder LS, Regev A: Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009, 15 (7): 719-729. 10.1002/lt.21692.
15. Polson J, Lee WM, American Association for the Study of Liver D: AASLD position paper: the management of acute liver failure. Hepatology. 2005, 41 (5): 1179-1197. 10.1002/hep.20703.
16. Zimmerman HJ: Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 1999, Philadelphia, Lippincott Williams & Wilkins, 2
17. Reuben A: Hy's law. Hepatology. 2004, 39 (2): 574-578. 10.1002/hep.20081.
18. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005, 129 (2): 512-521. 10.1016/j.gastro.2005.05.006.
19. Bjornsson E, Olsson R: Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42 (2): 481-489. 10.1002/hep.20800.
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER): Guidance for industry drug-induced liver injury: premarketing clinical evaluation. 2009
21. Gomez-Gil E, Salmeron JM, Mas A: Phenelzine-induced fulminant hepatic failure. Ann Intern Med. 1996, 124 (7): 692-693.
22. Hollinrake K: Acute hepatic necrosis associated with ethionamide. Br J Dis Chest. 1968, 62 (3): 151-154. 10.1016/S0007-0971(68)80006-3.